Literature DB >> 20032181

Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity.

Baibaswata Nayak1, Sachin Kumar, Joshua M DiNapoli, Anandan Paldurai, Daniel R Perez, Peter L Collins, Siba K Samal.   

Abstract

Highly pathogenic avian influenza virus (HPAIV) subtype H5N1 causes severe disease and mortality in poultry. Increased transmission of H5N1 HPAIV from birds to humans is a serious threat to public health. We evaluated the individual contributions of each of the three HPAIV surface proteins, namely, the hemagglutinin (HA), the neuraminidase (NA), and the M2 proteins, to the induction of HPAIV-neutralizing serum antibodies and protective immunity in chickens. Using reverse genetics, three recombinant Newcastle disease viruses (rNDVs) were engineered, each expressing the HA, NA, or M2 protein of H5N1 HPAIV. Chickens were immunized with NDVs expressing a single antigen (HA, NA, and M2), two antigens (HA+NA, HA+M2, and NA+M2), or three antigens (HA+NA+M2). Immunization with HA or NA induced high titers of HPAIV-neutralizing serum antibodies, with the response to HA being greater, thus identifying HA and NA as independent neutralization antigens. M2 did not induce a detectable neutralizing serum antibody response, and inclusion of M2 with HA or NA reduced the magnitude of the response. Immunization with HA alone or in combination with NA induced complete protection against HPAIV challenge. Immunization with NA alone or in combination with M2 did not prevent death following challenge, but extended the time period before death. Immunization with M2 alone had no effect on morbidity or mortality. Thus, there was no indication that M2 is immunogenic or protective. Furthermore, inclusion of NA in addition to HA in a vaccine preparation for chickens may not enhance the high level of protection provided by HA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032181      PMCID: PMC2820928          DOI: 10.1128/JVI.02135-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

1.  Development of effective vaccines against pandemic influenza.

Authors:  Kanta Subbarao; Brian R Murphy; Anthony S Fauci
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

Review 2.  Evolution and ecology of influenza A viruses.

Authors:  R G Webster; W J Bean; O T Gorman; T M Chambers; Y Kawaoka
Journal:  Microbiol Rev       Date:  1992-03

3.  Characterization of cholesterol-free insect cells infectible by baculoviruses: effects of cholesterol on VSV fusion and infectivity and on cytotoxicity induced by influenza M2 protein.

Authors:  D Z Cleverley; H M Geller; J Lenard
Journal:  Exp Cell Res       Date:  1997-06-15       Impact factor: 3.905

4.  Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.

Authors:  Jinying Ge; Guohua Deng; Zhiyuan Wen; Guobing Tian; Yong Wang; Jianzhong Shi; Xijun Wang; Yanbing Li; Sen Hu; Yongping Jiang; Chinglai Yang; Kangzhen Yu; Zhigao Bu; Hualan Chen
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

5.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates.

Authors:  Haichen Song; Gloria Ramirez Nieto; Daniel R Perez
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

7.  Toxicity of influenza A virus matrix protein 2 for mammalian cells is associated with its intrinsic proton-channeling activity.

Authors:  Petr O Ilyinskii; Vladimir L Gabai; Shamil R Sunyaev; Galini Thoidis; Alexander M Shneider
Journal:  Cell Cycle       Date:  2007-06-12       Impact factor: 4.534

8.  Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.

Authors:  Wanli Liu; Peng Zou; Ying-Hua Chen
Journal:  Immunol Lett       Date:  2004-05-15       Impact factor: 3.685

Review 9.  A "universal" human influenza A vaccine.

Authors:  W Fiers; M De Filette; A Birkett; S Neirynck; W Min Jou
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

10.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

View more
  29 in total

1.  Biological and protective properties of immune sera directed to the influenza virus neuraminidase.

Authors:  Stefan J Halbherr; Thomas H Ludersdorfer; Meret Ricklin; Samira Locher; Marianne Berger Rentsch; Artur Summerfield; Gert Zimmer
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Replication-incompetent influenza A viruses that stably express a foreign gene.

Authors:  Makoto Ozawa; Sylvia T Victor; Andrew S Taft; Shinya Yamada; Chengjun Li; Masato Hatta; Subash C Das; Emi Takashita; Satoshi Kakugawa; Eileen A Maher; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Gen Virol       Date:  2011-08-31       Impact factor: 3.891

Review 4.  Evasion of innate and adaptive immune responses by influenza A virus.

Authors:  Mirco Schmolke; Adolfo García-Sastre
Journal:  Cell Microbiol       Date:  2010-05-06       Impact factor: 3.715

5.  Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.

Authors:  Sunil K Khattar; Sweety Samal; Anthony L Devico; Peter L Collins; Siba K Samal
Journal:  J Virol       Date:  2011-08-17       Impact factor: 5.103

6.  Highly pathogenic avian influenza virus subtype H5N1 escaping neutralization: more than HA variation.

Authors:  Dirk Höper; Donata Kalthoff; Bernd Hoffmann; Martin Beer
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

7.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

8.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

9.  Rescue of a recombinant Newcastle disease virus strain R2B expressing green fluorescent protein.

Authors:  Madhan Mohan Chellappa; Sohini Dey; Satish Gaikwad; Dinesh C Pathak; Vikram N Vakharia
Journal:  Virus Genes       Date:  2017-02-09       Impact factor: 2.332

10.  Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins.

Authors:  Nicholas S Heaton; David Sachs; Chi-Jene Chen; Rong Hai; Peter Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.